Diabetes Care and CamDiab are pleased to announce that Health Canada has approved the use of mylife Loop powered by mylife ...

Abbott, the creator of continuous glucose monitors, launched the new Assist feature at CES 2026. Part of the Libre app, it aims to help people with diabetes take the guesswork out of how food affects ...

Abbott’s (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in every province across ...

In early January 2026, Abbott Laboratories unveiled Libre Assist, an AI-powered feature within its Libre app that helps U.S. diabetes patients predict the glucose impact of meals in real time by ...

Libre Assist 1 uses generative AI to predict how a food choice may affect a person’s glucose levels. 2 It then offers actionable and personalized meal guidance 3 to support in-the-moment decisions.

ABBOTT PARK, Ill. - Abbott (NYSE:ABT) introduced Libre Assist, a new feature within its Libre app designed to help people with diabetes make informed food choices before eating, the healthcare company ...

Abbott is tapping the spirit of new beginnings for the New Year by unveiling a “gamechanger" feature within the company’s Libre app: Libre Assist. Timed to launch during this week’s CES 2026 ...

The Libre Assist feature. [Image courtesy of Abbott] Abbott (NYSE:ABT) today unveiled a new feature within its Libre app for continuous glucose monitoring (CGM). Libre Assist, the new feature, aims to ...